Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

Food and Drug Administration

Description

This grant opportunity aims to study the effectiveness of an in vitro gastrointestinal dissolution model to evaluate amorphous solid dispersion (ASD) drug products. The focus is on understanding how food and acid-reducing agents affect drug absorption, considering different formulations of drugs. By refining and validating this methodology, it seeks to predict in vivo outcomes and guide the requirements for bioequivalence studies. The ultimate goal is to improve regulatory decisions and redu…

The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to dev…

Source

Grant ID

FOR-FD-24-005

Funding Source

Food and Drug Administration

Eligibility

The following categories of applicants are invited to apply:

  • Native American tribal governments (Federally recognized)
  • City or township governments
  • Independent school districts
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Public housing authorities/Indian housing authorities
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • For profit organizations other than small businesses
  • Small businesses
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Special district governments
  • County governments
  • State governments
  • Public and State controlled institutions of higher education
  • Private institutions of higher education
Additional Eligibility Information
Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmi…
Awards & Funding

Award Ceiling

$500,000

Award Floor

$250,000

Funding Amount

Discretionary

Links
Similar opportunities

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.